Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer - Test2 - elhamkhani - TriplyDB

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

http://www.wikidata.org/entity/Q33977247

about

Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.Strategies to Inhibit Myc and Their Clinical Applicability MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET.Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Glucose Metabolism Reprogrammed by Overexpression of IKKε Promotes Pancreatic Tumor Growth.The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.Characterization of SET/I2PP2A isoforms in dogs.MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation.Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.SET contributes to the epithelial-mesenchymal transition of pancreatic cancer.Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.Therapeutic Targeting of PP2A.KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Phosphopeptide Enrichment and LC-MS/MS Analysis to Study the Phosphoproteome of Recombinant Chinese Hamster Ovary Cells.CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma.Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications

P2860

Q27308683-1335EB18-9EDA-4C5A-A355-E060A5E45DC1 Q36020877-5A5E68D7-C076-4178-B75E-7D1AD69B2110 Q36275673-47AD8861-34D2-47E4-B1AC-44BA595A8096 Q36303678-7FC56CB8-7439-468F-B4BA-033038E43770 Q36982248-8444F69E-56D6-4A38-815C-901D0AE4E8A3 Q38228491-1598AD96-A19F-47C6-A38C-3251022797F8 Q38678579-5F59A4BF-A94F-4D3E-AFAE-DCE257425DB1 Q38727377-9EED0736-D71E-46C2-8898-8993E81294C2 Q38865301-A5910026-1695-44EC-8ACE-D8051EB84BB6 Q38869675-6AE110C2-896A-4735-930F-804CDE27F698 Q38988359-A516A72E-1227-42A4-864E-C9F3180E1FB3 Q41553595-372749DE-946A-45DC-9B4F-9667629F5B98 Q41809641-7FD1FDC8-917B-4870-8942-64E083836F8F Q41976132-1373925D-8A3B-4139-B50C-D5BD322F320D Q42100343-B50634BB-5C33-4F7A-A8B1-0C4E7AA22C1F Q42152408-FC9BCF15-F0E5-41AD-806A-F3532569ACB8 Q47111931-8DCFAC7A-957E-4F57-BA00-7E45BEDFFE03 Q47436859-67C8B0F9-C948-4412-B6B4-53EA50B51CF7 Q47563012-3FE1706D-AE11-4163-9E4E-60D0520B9CE5 Q51009101-48A588B6-227C-428A-8209-06A5866E8D34 Q51158345-040E0D3E-A0C8-4F7E-97F0-84EC2AC8E07C Q58374470-39FD7283-54D0-40B5-BBB5-CFD45C86E7B9

P2860

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

http://www.wikidata.org/entity/Q33977247

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

@ast

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

@en

type

label

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

@ast

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

@en

prefLabel

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

@ast

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

@en

P1433

Q33977247-7E56DA41-712C-4FE4-ACFA-CD011C37B854

P1476

Q33977247-40E3EFFF-8153-4A5F-BD5C-669309AFD60A

P2093

Q33977247-051F6C32-1D3D-4869-B839-1DD0149470FF

Q33977247-0B3B6B7C-5A12-426A-9E86-DEADD7F2A7F6

Q33977247-215F79FB-88B1-4225-AED4-8617160D9CCB

Q33977247-26769D2E-D2F8-4402-800D-240EDC3E3FAE

Q33977247-2AF02CBB-4BB7-4AC5-A51B-8164CB774BDF

Q33977247-2E515536-D400-485F-BC4C-83F116866BC6

Q33977247-707940C9-91C2-4A89-8D7F-6F4F66AB0D9E

Q33977247-9C261E94-D76C-4E3A-B9C2-1DB1F5953FED

Q33977247-ABA0F4AF-3F06-4A1C-A8AE-4271DD182716

Q33977247-B8347F32-17FC-4F47-A281-B8139776CB52

P2860

Q33977247-0207215E-02D2-43FB-B2CC-4E6A9F8FE925

Q33977247-0AA379CF-8A58-4DD7-9DBE-142D019A237C

Q33977247-18733341-58B8-478C-8769-F0FA1F663B0D

Q33977247-1CB10B13-D493-491C-9785-A039E04E9A7E

Q33977247-279C7608-2225-4531-B417-39935DCDB063

Q33977247-33F32447-EC22-4335-9CFA-49ADEB1CEBB5

Q33977247-3440FEFB-6777-48FD-9F92-E58BE1D5F6B2

Q33977247-39AF68E5-1E74-472B-AF67-AC929FB85366

Q33977247-3CCD3D9D-FF6C-4D2C-9619-89985A49B203

Q33977247-3F959BA3-9693-483D-8939-A6D896166249

P304

Q33977247-1F36FF6A-CD8A-43EC-8F00-661D9AF7954D

P31

Q33977247-AB93A4BA-4D43-402D-B9E2-75D6E6504E41

P356

Q33977247-79423978-DF11-4D49-AB0A-01900C9C5DBE

P433

Q33977247-890258F4-1AF9-4EF8-B2B8-54D0AC053E06

P478

Q33977247-E9E7DA60-47F1-432D-8AE8-1F6667542ECD

P50

Q33977247-1989D887-7E3C-4C82-A95C-F49568C3316B

Q33977247-DFF9B481-5104-4EF3-8CEA-6B1CF8A75E0D

P577

Q33977247-D3B81F66-43A9-49A8-AE44-D60F99480653

P5875

Q33977247-5BBC325A-EDB4-4920-B71C-A75992DF0B1E

P698

Q33977247-7A07ECFD-6093-4D88-8640-442502A277B0

P932

Q33977247-349D3833-AFEC-4403-9279-BDF3F0F180BC

P356

1541-7786.MCR-13-0542

P1433

Molecular Cancer Research

P1476

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

@en

P2093

Amy S Farrell

http://www.w3.org/2001/XMLSchema#string

Charles Lopez

http://www.w3.org/2001/XMLSchema#string

Colin J Daniel

http://www.w3.org/2001/XMLSchema#string

Dale J Christensen

http://www.w3.org/2001/XMLSchema#string

Jessica Oddo

http://www.w3.org/2001/XMLSchema#string

Michael P Vitek

http://www.w3.org/2001/XMLSchema#string

Rosalie C Sears

http://www.w3.org/2001/XMLSchema#string

Sarah Rodriguez

http://www.w3.org/2001/XMLSchema#string

Soren Impey

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A

CIP2A inhibits PP2A in human malignancies

PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor

Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation

Cancer statistics, 2009

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

P304

924-939

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1541-7786.MCR-13-0542

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Brett C Sheppard

Brittany L Allen-Petersen

P577

2014-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261103538

http://www.w3.org/2001/XMLSchema#string

P698

24667985

http://www.w3.org/2001/XMLSchema#string

P932

4116560

http://www.w3.org/2001/XMLSchema#string